HomeOpen Access NewsSH - Secarna Pharmaceuticals GmbH & Co. KG

SH - Secarna Pharmaceuticals GmbH & Co. KG

Subscribe to Updates

Unraveling the potential of antisense therapies to target neuropilin 1 in the fight against cancer

Cancer Research
Secarna Pharmaceuticals, the next-generation antisense drug discovery and development company, is developing novel approaches to successfully target Neuropilin 1 (NRP1), a promising target for the treatment of cancer.

Antisense therapies: A new approach to tackling challenging targets in areas of high unmet medical need

Health & Social Care
Alexander Gebauer, the Chief Executive Officer at Secarna Pharmaceuticals GmbH & Co. KG looks at a new approach to solve unmet medical needs with...

Secarna aims to expand the therapeutic toolbox against cancer

Cancer Research
Current oncology treatments have significantly improved cancer survival rates, but more effective and safer therapeutics are needed.

Secarna: Next generation antisense therapeutics

Pharma
Leading independent European antisense drug discovery company, Secarna, aims to bring novel and effective antisense therapeutic options to an increasing number of patients. CEO Alexander Gebauer tells us how.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders

Visit Article Archive
Open Access Government

Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.

Follow Us

Resources

Quick Links

Legal & Marketing

As a Crossref Sponsored Member we are able to connect your content with a global network of online scholarly research, currently over 20,000 other organizational members from 160 countries. Crossref drive metadata exchange and support nearly 2 billion monthly API queries, facilitating global research communication.

© Adjacent Digital Politics Ltd